X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (209) 209
male (184) 184
female (152) 152
endocrinology & metabolism (127) 127
middle aged (123) 123
index medicus (108) 108
adult (106) 106
animals (71) 71
aged (59) 59
rats (59) 59
japan (44) 44
obesity (42) 42
information storage (39) 39
information storage based on relative movement between recordcarrier and transducer (39) 39
physics (39) 39
cardiovascular (35) 35
cardiac & cardiovascular systems (33) 33
rats, inbred strains (33) 33
risk factors (26) 26
analysis (22) 22
diabetes (22) 22
atherosclerosis (20) 20
medicine & public health (20) 20
peripheral vascular disease (20) 20
treatment outcome (20) 20
expression (19) 19
metabolic syndrome (19) 19
adolescent (18) 18
diagnosis (18) 18
dose-response relationship, drug (18) 18
aged, 80 and over (17) 17
biomarkers - blood (17) 17
body mass index (17) 17
growth hormone (17) 17
mice (16) 16
prolactin - blood (16) 16
cardiovascular-disease (15) 15
therapy (15) 15
adenoma - metabolism (14) 14
child (14) 14
prolactin - metabolism (14) 14
prospective studies (14) 14
young adult (14) 14
acromegaly (13) 13
biochemistry & molecular biology (13) 13
care and treatment (13) 13
cell biology (13) 13
disease (13) 13
human growth hormone - deficiency (13) 13
inflammation (13) 13
injections, intraventricular (13) 13
pituitary neoplasms - metabolism (13) 13
thyrotropin-releasing hormone - pharmacology (13) 13
cross-sectional studies (12) 12
hypertension (12) 12
internal medicine (12) 12
medicine, general & internal (12) 12
peptides - pharmacology (12) 12
quality of life (12) 12
research (12) 12
time factors (12) 12
women (12) 12
adiponectin (11) 11
body composition (11) 11
follow-up studies (11) 11
human growth hormone - therapeutic use (11) 11
low density lipoproteins (11) 11
mortality (11) 11
pituitary (11) 11
prognosis (11) 11
protein (11) 11
retrospective studies (11) 11
risk (11) 11
safety (11) 11
secretion (11) 11
smoking cessation (11) 11
tumors (11) 11
asian continental ancestry group (10) 10
cholesterol (10) 10
dyslipidemia (10) 10
growth hormone - secretion (10) 10
hypopituitarism (10) 10
insulin-like growth factor i - analysis (10) 10
insulin-like growth factor i - metabolism (10) 10
kinetics (10) 10
management (10) 10
original (10) 10
patients (10) 10
prolactin (10) 10
risk-factors (10) 10
smoking (10) 10
adenoma - pathology (9) 9
arterial stiffness (9) 9
body-composition (9) 9
cells, cultured (9) 9
endocrinology (9) 9
ghrelin (9) 9
growth hormone - blood (9) 9
heart failure (9) 9
human growth hormone - administration & dosage (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2017, Volume 35, Issue 4, pp. 499 - 508
Background Lanreotide is a long-acting somatostatin analog with demonstrated efficacy against enteropancreatic neuroendocrine tumor (NET) in the phase III... 
Medicine & Public Health | Lanreotide | Oncology | Phase II | Pharmacology/Toxicology | Neuroendocrine tumor | Japanese | Somatostatin analog | ONCOLOGY | ANALOGS | PHARMACOLOGY & PHARMACY | SOMATOSTATIN RECEPTORS | Pancreatic Neoplasms - metabolism | Somatostatin - adverse effects | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Pancreatic Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Gastrointestinal Neoplasms - metabolism | Somatostatin - analogs & derivatives | Gels | Neuroendocrine Tumors - metabolism | Kaplan-Meier Estimate | Treatment Outcome | Somatostatin - pharmacokinetics | Peptides, Cyclic - pharmacokinetics | Peptides, Cyclic - blood | Disease-Free Survival | Asian Continental Ancestry Group | Somatostatin - blood | Antineoplastic Agents - blood | Neuroendocrine Tumors - drug therapy | Peptides, Cyclic - therapeutic use | Aged | Somatostatin - therapeutic use | Peptides, Cyclic - adverse effects | Complications and side effects | Dosage and administration | Somatostatin | Research | Fas antigen | Midgut | Hindgut | Diabetes mellitus | Pharmacology | Injection | Patients | Survival | Metastases | Confidence intervals | Studies | Lungs | Multiple endocrine neoplasia | Safety | Feces | Pancreas | Pharmacokinetics | Foregut | Tumors | Neuroendocrine tumors | Phase II Studies
Journal Article
Journal Article
Modern Rheumatology, ISSN 1439-7595, 2/2012, Volume 22, Issue 1, pp. 21 - 30
Journal Article
Journal Article
Nihon Naika Gakkai Zasshi, ISSN 0021-5384, 2016, Volume 105, Issue 4, pp. 683 - 689
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 2/2010, Volume 45, Issue 2, pp. 234 - 243
Journal Article
ENDOCRINE JOURNAL, ISSN 0918-8959, 2012, Volume 59, Issue 12, pp. 1137 - 1137
Dear Sir; Akahori [1] reported an interesting case of possible lymphocytic hypophysitis with reversible impaired processing of proopiomelanocortin into ACTH.... 
Journal Article
Endocrine Journal, ISSN 0918-8959, 2012, Volume 59, Issue 12, pp. 1137 - 1137
Journal Article
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 03/2013, Volume 98, Issue 3, pp. 1130 - 1136
Journal Article
Endocrine Journal, ISSN 0918-8959, 2017, Volume 64, Issue 7, pp. 735 - 747
A multicenter, open-label, phase 2 study was conducted to investigate the efficacy and safety of long-acting pasireotide formulation in Japanese patients with... 
Acromegaly | Insulin-like growth factor-1 | Pasireotide | Growth hormone | Japanese | SOMATOSTATIN ANALOGS | METAANALYSIS | EXTENSION | OCTREOTIDE LAR | TRIAL | THERAPY | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | TERM SAFETY | LANREOTIDE | Nasopharyngitis - physiopathology | Gigantism - blood | Somatostatin - adverse effects | Gigantism - drug therapy | Humans | Middle Aged | Nasopharyngitis - chemically induced | Somatostatin - administration & dosage | Male | Patient Dropouts | Delayed-Action Preparations - administration & dosage | Dose-Response Relationship, Drug | Hyperglycemia - chemically induced | Hypoglycemia - physiopathology | Adult | Female | Acromegaly - blood | Hyperglycemia - physiopathology | Hypoglycemia - chemically induced | Severity of Illness Index | Reproducibility of Results | Somatostatin - analogs & derivatives | Constipation - physiopathology | Insulin-Like Growth Factor I - analysis | Constipation - chemically induced | Acromegaly - drug therapy | Delayed-Action Preparations - adverse effects | Diabetes Mellitus - physiopathology | Delayed-Action Preparations - therapeutic use | Diabetes Mellitus - chemically induced | Human Growth Hormone - blood | Aged | Somatostatin - therapeutic use | Drug Monitoring | Dopamine | Gigantism | Insulin-like growth factor I | Diabetes mellitus | Liver | Rhinopharyngitis | Insulin-like growth factors | Hypoglycemia | Insulin | Patients | Hyperglycemia | Pituitary | Growth hormones | Somatostatin | Diabetes | Constipation
Journal Article
Endocrine Journal, ISSN 0918-8959, 2013, Volume 60, Issue 5, pp. 651 - 663
The somatostatin analog lanreotide Autogel has proven to be efficacious for treating acromegaly in international studies and in clinical practices around the... 
Insulin-like growth factor-I | Acromegaly | Lanreotide Autogel | Growth hormone | Somatostatin analog | MANAGEMENT | THERAPY | ENDOCRINOLOGY & METABOLISM | EPIDEMIOLOGY | OCTREOTIDE LAR | Gigantism - blood | Somatostatin - adverse effects | Gigantism - drug therapy | Humans | Middle Aged | Somatostatin - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Peptides, Cyclic - administration & dosage | Delayed-Action Preparations - administration & dosage | Dose-Response Relationship, Drug | Acromegaly - etiology | Growth Hormone-Secreting Pituitary Adenoma - blood | Antineoplastic Agents - adverse effects | Adenoma - drug therapy | Delayed-Action Preparations - pharmacokinetics | Adult | Female | Acromegaly - prevention & control | Antineoplastic Agents - pharmacokinetics | Somatostatin - analogs & derivatives | Gels | Japan | Insulin-Like Growth Factor I - analysis | Down-Regulation - drug effects | Somatostatin - pharmacokinetics | Growth Hormone-Secreting Pituitary Adenoma - drug therapy | Peptides, Cyclic - pharmacokinetics | Growth Hormone-Secreting Pituitary Adenoma - physiopathology | Adenoma - physiopathology | Adenoma - blood | Delayed-Action Preparations - adverse effects | Delayed-Action Preparations - therapeutic use | Peptides, Cyclic - therapeutic use | Human Growth Hormone - blood | Aged | Somatostatin - therapeutic use | Drug Monitoring | Peptides, Cyclic - adverse effects | Gastrointestinal Diseases - chemically induced | Pituitary Gland - drug effects
Journal Article
Journal of Clinical Biochemistry and Nutrition, ISSN 0912-0009, 2017, Volume 61, Issue 3, pp. 217 - 221
We assessed whether gut microbial functional profiles predicted from 16S rRNA metagenomics differed in Japanese type 2 diabetic patients. A total of 22... 
prediction of functional profiles | diabetes | glucose metabolism | genus Blautia | dysbiosis | Glucose metabolism | Prediction of functional profiles | Diabetes | Dysbiosis | Genus blautia | Dysbacteriosis | Diabetes mellitus | rRNA 16S | Original
Journal Article
Journal Article
Endocrine Journal, ISSN 0918-8959, 2017, Volume 64, Issue 7, pp. 651 - 662
We aimed to evaluate the long-term safety and effectiveness of growth hormone (GH) therapy in Japanese patients with adult growth hormone deficiency (AGHD). In... 
Somatropin | Postmarketing | Safety | Japan | Growth hormone deficiency | MORTALITY | EFFICACY | GH REPLACEMENT THERAPY | BODY-COMPOSITION | DIABETES-MELLITUS | DATABASE | HYPOPITUITARY PATIENTS | CRANIOPHARYNGIOMA | ENDOCRINOLOGY & METABOLISM | RECURRENCE | CARDIOVASCULAR RISK | Recombinant Proteins - therapeutic use | Follow-Up Studies | Congenital Hypothyroidism - blood | Humans | Middle Aged | Dwarfism, Pituitary - drug therapy | Male | Hormone Replacement Therapy - adverse effects | Patient Dropouts | Recombinant Proteins - adverse effects | Congenital Hypothyroidism - drug therapy | Young Adult | Human Growth Hormone - therapeutic use | Dwarfism, Pituitary - blood | Product Surveillance, Postmarketing | Adult | Female | Human Growth Hormone - administration & dosage | Lost to Follow-Up | Human Growth Hormone - genetics | Medical Records | Human Growth Hormone - adverse effects | Biomarkers - blood | Sex Characteristics | Recombinant Proteins - administration & dosage | Congenital Hypothyroidism - ethnology | Dwarfism, Pituitary - ethnology | Drug Monitoring | Dual energy X-ray absorptiometry | Lipoproteins (low density) | Medical records | Metabolism | Patients | Body composition | Cholesterol | Glucose metabolism | Growth hormones | Lipid metabolism | Growth hormone | Physical growth | Lipoproteins (high density)
Journal Article